RecruitingNCT05961969
Robotic Top-down Intersphincteric Resection
A Feasibility Study of Robotic Transabdominal Top-down Intersphincteric Resection With Double-stapling Coloanal Anastomosis for Distal Rectal Cancer
Sponsor
National Taiwan University Hospital
Enrollment
40 participants
Start Date
Feb 21, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The present study is to develop the novel robotic surgical technique and enhance the surgery quality for the treatment of distal rectal cancer.
Eligibility
Min Age: 20 YearsMax Age: 75 Years
Inclusion Criteria5
- cT1-3 or yT 1-3 rectal adenocarcinoma whose low border was located below the anorectal sling (4 cm from anal verge), in which the required surgery meets the definition of ISR;
- Clinically Tumor-Node-Metastasis (TNM) stage I-III rectal adenocarcinoma;
- Curative and elective surgery;
- American Society of Anesthesiology (ASA) class Ⅰ to Ⅲ patients;
- Age between 20 and 75 years.
Exclusion Criteria6
- cT4 adenocarcinoma, i.e., the rectal cancer invaded to external sphincter or adjacent pelvic organs;
- Evidence of distant metastasis;
- Primary tumor mass≧8 cm in diameter;
- Morbidly obese patients, i.e., body mass index (BMI) ≧ 40 kg/m2 ;
- Previous major surgery of low upper abdomen;
- The adenocarcinoma has invaded to lateral pelvic side wall requiring a lateral pelvic lymph node dissection. (7) Patients with poor anorectal function (Wexner incontinence Score≧ 10)
Interventions
PROCEDURERobotic surgery
1. Patients with rectal cancer. 2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05961969
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations